Telix And Ekalia, IBA-Framatome Joint Venture, Collaborate On US Astatine-211 Production, Securing Priority Isotope Access For TLX102-Tx Glioblastoma Pipeline

Telix Pharmaceuticals has entered into a collaboration with Ekalia, a joint venture of IBA and Framatome, to establish a dedicated U.S. source for astatine-211 (211At), an isotope crucial for targeted alpha therapy. This partnership ensures long-term priority access to 211At for Telix's TLX102-Tx pipeline aimed at treating glioblastoma and supports other academic and industry programs. The first IBA alpha-beam cyclotron will be installed at Telix's RLS Radiopharmacies site in Philadelphia, with potential for further installations as demand increases.